Pharma challenge narrows

Large branded drugmakers and trade groups challenge the proposal, arguing it conflicts with FDA compounding law and undermines approved medicines. The administration still supports peptide access, but legal pressure forces a narrower or delayed implementation.

Each figure is the modeled move of the S&P 500 if the outcome occurs. For information only. Not investment advice.